Latest News of VKTX
Viking Therapeutics Inc (VKTX) Q3 2024 Earnings Call Highlights: Strong Financial Position Amid ...
By Yahoo! Finance |
1 week ago
Brian Lian, President and CEO, discusses plans for monthly dosing, combination testing with amylin, safety expectations for higher doses, and the value split between subcutaneous and oral forms of VK2...
With 74% institutional ownership, Viking Therapeutics, Inc. (NASDAQ:VKTX) is a favorite amongst the big guns
By Yahoo! Finance |
3 weeks ago
In Viking Therapeutics, 16 investors hold a majority stake of 51%. Institutions are the largest shareholders with 74% ownership, influencing the company's performance. Insider ownership aligns with bo...
Viking Therapeutics, Inc. (VKTX): A Hot Stock to Buy Now
By Yahoo! Finance |
4 weeks ago
A list of hot stocks includes Viking Therapeutics, Inc. amid market pressures like the ILA port strike and Hurricane Helene's impact. Analysts favor VKTX for its promising drug trials, with an 83.87% ...
-
Is Viking Therapeutics, Inc. (VKTX) the Best Performing Long Term Stock in 2024?
By Yahoo! Finance | 1 month agoIn our latest article, we analyze Viking Therapeutics, Inc. (NASDAQ:VKTX) as one of the top long-term performing stocks in 2024....
-
Is Viking Therapeutics Inc. (VKTX) the Best Performing Small-Cap Stock in 2024?
By Yahoo! Finance | 1 month agoThe article discusses the market trends, with a focus on Viking Therapeutics Inc. as one of the best-performing small-cap stocks in 2024. It also highlights Richard Bernstein's insights on small-cap s...
-
Viking Therapeutics, Inc. (VKTX): Biotech Breakthrough or Short Sellers' Target?
By Yahoo! Finance | 1 month agoIn a recent article, Viking Therapeutics, Inc. (NASDAQ:VKTX) is analyzed against other worst booming stocks to buy according to short sellers. Despite being on the list, VKTX shows growth potential wi...
-
Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX
By Yahoo! Finance | 1 month agoAmateur investors often complicate their strategies with excessive indicators. Simplifying by focusing on key tools like the 200-day moving average can aid in trend identification, risk management, an...
-
Viking Therapeutics, Inc. (VKTX): One of Oppenheimer's Top Stock Picks For the Next 12 Months
By Yahoo! Finance | 2 months agoOppenheimer's top stock picks for the next 12 months include Viking Therapeutics, Inc. (NASDAQ:VKTX), a biotech company with promising drug candidates for liver diseases and weight loss. Despite its p...
-
Director J Singleton Sells 5,700 Shares of Viking Therapeutics Inc (VKTX)
By Yahoo! Finance | 2 months agoViking Therapeutics Inc is a biopharmaceutical company focusing on metabolic disorders. An insider sold shares valued at $397,404, part of a trend with no insider buys in a year. Investors can track i...
-
Director J Singleton Sells 16,000 Shares of Viking Therapeutics Inc (VKTX)
By Yahoo! Finance | 2 months agoViking Therapeutics Inc is focused on developing therapies for metabolic disorders. An insider recently sold shares worth $995,520, part of a trend with more sales than purchases. Investors can monito...
-
Why Is Viking Therapeutics, Inc. (VKTX) the Best Diabetes Stock to Buy Now?
By Yahoo! Finance | 2 months agoAn overview of the growing diabetes market, focusing on Viking Therapeutics, Inc. as a key player in the field of diabetes and weight reduction medications. Viking's experimental weight reduction inje...
-
Director J Singleton Sells 20,786 Shares of Viking Therapeutics Inc (VKTX)
By Yahoo! Finance | 2 months agoViking Therapeutics Inc is a biopharmaceutical company focusing on metabolic therapies. The recent insider sell of shares at $57.53 impacts the company's market cap of $6.45 billion. The trend of insi...
-
Is Viking Therapeutics, Inc. (VKTX) a Good Addition to Your Portfolio Right Now?
By Yahoo! Finance | 2 months agoViking Therapeutics (NASDAQ:VKTX) shows promise in the competitive GLP-1 and weight loss market, with its VK2735 drug demonstrating significant weight reduction. With positive Phase 2 results and a po...
-
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
By Yahoo! Finance | 3 months agoViking Therapeutics reported a narrower Q2 loss, with no approved products yet. Expenses increased due to drug candidate manufacturing. The company's promising drug VK2735 for obesity is advancing to ...
-
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History
By Yahoo! Finance | 3 months agoViking Therapeutics is a biopharmaceutical company developing therapies for metabolic disorders. Their lead drug candidate, VK2809, is in Phase IIb trials for non-alcoholic steatohepatitis....